A Phase 3 interventional study of Infliximab + methotrexate (MTX) in Arthritis, Rheumatoid, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing infliximab in Arthritis, Rheumatoid — 2 open to participants now, 3 under way, 1 of them phase 3. Infliximab · Arthritis, Rheumatoid.
Among the 49 studies testing infliximab in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 2 that started in 2006, is one of 19 in phase 3, and was the 16th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 49 studies testing infliximab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is close to the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 172 across the 49 interventional studies. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
30 studies in Arthritis, Rheumatoid by Merck & Co., Inc: 2 open now, 3 under way, none of them phase 3. Of 25 finished, 18 (72%) have results posted.
Among the 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2006, is one of 5 in phase 3, and was the 16th registered.
Merck & Co., Inc’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing infliximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 30 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
[Main double-blind study (P04280, NCT00202852) inclusion criteria]
Active disease at the time of screening and pre-infusion as defined by:
2 of the following:
The screening laboratory tests must meet the following criteria:
Exclusion Criteria:
[Main double-blind study (P04280, NCT00202852) exclusion criteria]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
Biological: Infliximab + methotrexate (MTX)
Drug pages: Infliximab · Methotrexate
Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
Also known as: Remicade, SCH 215596
Number of Subjects Experiencing Any Adverse Event
Time frame: throughout entire study (61 +/- 28.9 weeks on average)
Number of Subjects Experiencing Serious Adverse Event
Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.
Time frame: throughout entire study (61 +/- 28.9 weeks on average)
Number of Subjects Experiencing Any Infection
Time frame: throughout entire study (61 +/- 28.9 weeks on average)
Subjects showing clinical response at Week 30 of a previous double-blind study of infliximab vs placebo (P04280,NCT00202852) were eligible for this study. A total of 105 subjects were eligible (67 from previous placebo \& 38 from previous infliximab group) for this extension study, among whom a total of 92 enrolled to participate in the extension.
| Milestone | Open Label Infliximab + Methotrexate |
|---|---|
| Started | 92 |
| Completed | 57 |
| Not completed | 35 |
| Withdrew: Adverse event | 16 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lack of efficacy | 13 |
| participants | Open Label Infliximab + Methotrexate |
|---|---|
| Number of Subjects Experiencing Any Adverse Event | 76 |
Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.
| participants | Open Label Infliximab + Methotrexate |
|---|---|
| Number of Subjects Experiencing Serious Adverse Event | 12 |
| participants | Open Label Infliximab + Methotrexate |
|---|---|
| Number of Subjects Experiencing Any Infection | 41 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Infliximab + Methotrexate | — | 12/92 (13%) | 50/92 (54.3%) |
| Event | Open Label Infliximab + Methotrexate |
|---|---|
| chronic sinusitisInfections and infestations | 2/92 |
| arthralgiaMusculoskeletal and connective tissue disorders | 2/92 |
| urticariaSkin and subcutaneous tissue disorders | 2/92 |
| AnaemiaBlood and lymphatic system disorders | 1/92 |
| gastric ulcerGastrointestinal disorders | 1/92 |
| chest discomfortGeneral disorders | 1/92 |
| inflammationGeneral disorders | 1/92 |
| infusion related reactionGeneral disorders | 1/92 |
| ulcerGeneral disorders | 1/92 |
| cholecystitis acuteHepatobiliary disorders | 1/92 |
| Event | Open Label Infliximab + Methotrexate |
|---|---|
| upper respiratory tract infectionInfections and infestations | 19/92 |
| pruritusSkin and subcutaneous tissue disorders | 11/92 |
| urticariaSkin and subcutaneous tissue disorders | 9/92 |
| nauseaGastrointestinal disorders | 8/92 |
| headacheNervous system disorders | 8/92 |
| chillsGeneral disorders | 6/92 |
| nasopharyngitisInfections and infestations | 6/92 |
| alanine aminotransferase increasedInvestigations | 6/92 |
| coughRespiratory, thoracic and mediastinal disorders | 6/92 |
| diarrhoeaGastrointestinal disorders | 5/92 |
| Age, Continuous(years) | Open Label Infliximab + Methotrexate |
|---|---|
| Mean | 50.1 ± 11.1 |
| Age, Customized(participants) | Open Label Infliximab + Methotrexate |
|---|---|
| <30 years | 2 |
| Between 30 and less than 40 years | 14 |
| Between 40 and less than 50 years | 29 |
| Between 50 and less than 60 years | 29 |
| Between 60 and less than 70 years | 15 |
| >=70 years | 3 |
| Sex: Female, Male(Participants) | Open Label Infliximab + Methotrexate |
|---|---|
| Female | 86 |
| Male | 6 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Aug 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Infliximab · Methotrexate